1. Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study 
Andrew M. Erickson, Stefano Luzzago, Axel Semjonow, Hanna Vasarainen, Teemu D. Laajala, Gennaro Musi, Ottavio de Cobelli, Tuomas Mirtti, Antti Rannikko 
European Urology Oncology 
Volume 1, Issue 4, Pages (September 2018)
DOI: /j.euo
Copyright © Terms and Conditions

2. Fig. 1
Calculation of cumulative cancer locations (CCLO). (A) Locations from a standard biopsy procedure are dichotomized as positive or negative. (B) Positive locations from both diagnostic and confirmatory biopsies are summed to generate CCLO.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © Terms and Conditions

3. Fig. 2
Survival analyses by CCLO risk stratification in the pooled cohort. Kaplan-Meier survival curves for CCLO risk groups for (A) protocol-based discontinuation (PBD), (B) Gleason upgrading (GU), and (C) adverse radical prostatectomy findings (ARFP). CCLO=Cumulative Cancer Locations.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © Terms and Conditions

4. Fig. 3
Discriminatory analyses of CCLO risk groups versus the number of positive cores in confirmatory biopsy (CBx) for the pooled cohort. Receiver operating characteristic area under the curve (AUC) and 95% confidence interval for (A) protocol-based discontinuation, (B) Gleason upgrading, and (C) adverse radical prostatectomy findings. Decision curve analyses for (D) protocol-based discontinuation, (E) Gleason upgrading, and (F) adverse radical prostatectomy findings. CCLO=Cumulative Cancer Locations.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © Terms and Conditions